Breathe Well Live Well
|
First-in-class biologic maintenance therapy approved for severe asthma
ModernMedicine Nucala, developed by GlaxoSmithKline, is an interleukin-5 (IL-5) antagonist monoclonal antibody that reduces the production and survival of esosinophils, which are one of the inflammatory cell types involved in asthma. The biologic is to be … |
View full post on asthma – Google News
|
Asthma – Identifying and Commercializing First-in-Class InnovationAsthma …
Medgadget.com (blog) Analysis has confirmed the asthma pipeline to be highly active, with 252 products in active development across all stages. The range of mechanisms of action employed by these compounds is also highly diverse, especially in comparison to the existing … |
View full post on asthma – Google News
Medgadget.com (blog) |
Frontier Pharma: Asthma – Identifying and Commercializing First-in-Class …
Medgadget.com (blog) Analysis has confirmed the asthma pipeline to be highly active, with 252 products in active development across all stages. The range of mechanisms of action employed by these compounds is also highly diverse, especially in comparison to the existing … |
View full post on asthma – Google News
|
Frontier Pharma: Asthma – Identifying and Commercializing First-in-Class …
PR Newswire (press release) Analysis has confirmed the asthma pipeline to be highly active, with 252 products in active development across all stages. The range of mechanisms of action employed by these compounds is also highly diverse, especially in comparison to the existing … |
View full post on asthma – Google News
|
Asthma – Identifying and Commercializing First-in-Class Innovation by Market …
Medgadget.com (blog) Analysis has confirmed the asthma pipeline to be highly active, with 252 products in active development across all stages. The range of mechanisms of action employed by these compounds is also highly diverse, especially in comparison to the existing … |
View full post on asthma – Google News